363 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1567)
- Addiction (14)
- Allergy, Asthma, & Immunology (11)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (26)
- Blood Disorders (37)
- Bone & Muscle (8)
- Cancer
(639)
- Bladder Cancer (12)
- (-) Brain Cancer (15)
- Breast Cancer (64)
- Gastrointestinal (13)
- Gynecologic Cancer (24)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (71)
- Liver Cancer (9)
- Lung Cancer (59)
- Lymphoma (33)
- Multiple Myeloma (23)
- Pancreatic Cancer (15)
- Prostate Cancer (30)
- Sarcoma (25)
- Skin Cancer (28)
- Solid Tumors (44)
- Thyroid Cancer (1)
- (-) Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (28)
- Critical Illness (1)
- Dental (2)
- Developmental Disorders (2)
- Diabetes (13)
- Ear, Nose and Throat (5)
- Endocrine & Metabolic Disease (11)
- Eye (8)
- Gastrointestinal and Digestive Diseases (19)
- Hair and Skin Disorders (1)
- Headaches (5)
- Healthy Volunteers (131)
- Heart Disease (105)
- Infectious Disease (37)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (35)
- Lung Disease (29)
- Meniere's Disease (1)
- Neurological Disorders (131)
- Nutrition (3)
- Obesity (2)
- Obstetrics & Gynecology (40)
- Pain Management (1)
- Pediatrics (78)
- Psychiatric Disorders (57)
- Rehabilitation (7)
- Stroke (5)
- Surgery (7)
- Transplant (36)
- Urology (4)
- Vascular Conditions (9)
Displaying 1 - 22 of 22
Condition: Cancer / Brain Cancer
Investigator: Aya Haggiagi, MD
Status: Closed
Phase 2, Treatment A: This study is being done to see if your recurrent brain tumor may respond to a combination of radiosurgery (a type of radiation therapy) with nivolumab (a type of immunotherapy drug). A small number of patients have already received this combination previously and have tolerated the treatment relatively well. However, we would like to…
Condition: Cancer / Brain Cancer
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients with meningioma.…
Condition: Cancer / Uveal Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
This study will develop a data registry of patients diagnosed with uveal melanoma (UM). This registry will provide data that will be used to support the development of novel therapies for this disease. In this study, we are focused on trying to better understand how uveal melanoma behaves and how it is treated at different medical centers around the country.
Condition: Cancer / Brain Cancer
Investigator: Gurcharanjeet Kaur, MD
Status: Closed
The purpose of this study is to find out if REC-2282, an investigational new drug, is an effective and safe treatment in patients with progressive NF2 mutated meningiomas who have either NF2 disease-related meningioma or recurrent sporadic meningiomas that have NF2 mutation. Investigational new drug means a drug that has not been approved as a marketed…
Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved.
Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Closed
This study is being done to answer the following question: Can we shrink or stabilize your brain cancer by adding immune therapy drugs to the usual radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your recurrent glioblastoma. The usual approach is defined as care most…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to test the safety of a new vaccine, VBI-1901, and to know more about its ability to boost the response of the immune system against Cytomegalovirus. The reason for testing this vaccine in people with a brain tumor is that it might one day be used to boost the ability of the immune system to fight a certain type of brain tumor.…
Condition: Cancer / Brain Cancer
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to evaluate how safe the investigational drug, DSP-0390, is at different doses and to identify a recommended dose that is safe for further study. Investigational means that the study drug is currently being tested and has not been approved for use alone or in combination with any drug by the U.S. Food and Drug Administration (…
Condition: Cancer / Brain Cancer
Investigator: Brian Gill, MD
Status: Closed
The purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with a placebo see if it works in slowing glioblastoma multiforme (GBM) tumor regrowth. SOC refers to the usual medicine(s) or procedures used to treat your cancer. A placebo looks like the study medicine but does not contain any…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to evaluate and determine the efficacy of pemigatinib in participants with recurrent glioblastoma or other CNS tumors with changes in the FGFR1, FGFR2 or FGFR3 genes. Pemigatinib (also referred as INCB054828) is an investigational drug that is being studied by Incyte Corporation (Sponsor) for use in the treatment of previously…
Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Closed
Optune is a portable, battery-operated device that generates TTFields at a specific frequency. The TTFields are delivered to the brain through 4 sticky bandages (which hold ceramic discs) that are placed on the surface of the head (called arrays). The arrays create electric forces within the brain that disrupt cancer cell division. Optunes TTFields are a…
Condition: Cancer / Brain Cancer
Investigator: James Hinkley Garvin Jr, MD
Status: Closed
The purpose of this study is to find the best dose of a drug called MTX110 and a contrast agent called gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas, which is a kind of brain tumor. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to see if the combination of medications approved for the treatment of glioblastoma, together with the study drug, selinexor (also known as XPOVIO), has any effects on your cancer. Selinexor works by trapping tumor suppressor proteins within the cell nucleus. This is expected to cause the cancer cells to die or stop…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
This study is being done to evaluate the safety and usefulness of the study drug, AG-881, as compared to placebo (a medically inactive substance) in residual or recurrent non-enhancing Grade 2 glioma (a type of brain cancer) that has a mutation in the IDH1 or IDH2 metabolic enzyme (a substance produced by the body to assist in breaking down chemicals).…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to test how safe and how well an investigational drug known as ONC201 works in treating high grade glioma (a type of brain cancer). The FDA (the U.S. Food and Drug Administration) has not approved ONC201 as a treatment for this condition.
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests,…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is evaluate the benefits and safety of using the combination of drugs, AEB071 and BYL719 to treat patients with an advanced form of uveal melanoma. The study will have two parts. The first part twill test different dose levels of each drug.Once the highest safe dose level is found, another group of patients will be treated at that…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
You are invited to join voluntarily in a clinical research study to find out if the drug LXS196 alone or in combination with HDM201 is safe and has beneficial effects in people who have metastatic uveal melanoma. The purpose of this study is to determine the highest dose of LXS196 that can be given safely without unacceptable side effects as a single drug…
Condition: Cancer / Uveal Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
This research study is being done to see if the study drug, IMCgp100, works and is safe as treatment for subjects with uveal melanoma who also test positive for HLA-A*0201. In this study IMCgp100 will be compared to three standard treatments: dacarbazine (a chemotherapy drug), ipilimumab (an immunotherapy drug), or pembrolizumab (an immunotherapy drug).…
Condition: Cancer / Uveal Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the medication Selumetinib will have on you and your uveal melanoma. Selumetinib is a medication that blocks (or turns off) MEK, a protein activated in some uveal melanoma cells. Selumetinib is a MEK inhibitor. Blocking MEK may stop your cancer from growing.
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
This is a Phase I study of a weekly intra-patient escalation dose regimen with IMCgp100 in patients with metastatic uveal melanoma (mUM). To help decide whether or not patients can take part in a research study looking at a new form of treatment for advanced uveal melanoma, their blood need to first be tested to determine their Human Leukocyte Antigen (HLA…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the treatment part of the study is to find out what effects drug crizotinib has, good and/or bad on people with "high risk" uveal melanoma after surgery or radiation for the eye. It is thought that giving crizotinib to patients with "high risk" uveal melanoma can lower the chance the cancer will come back. Uveal melanoma…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE